Several reports have linked LIMCH1 depletion to cancer progression, suggesting reduced LIMCH1 levels may serve as a biomarker for tumor growth and metastasis in lung, breast, and cervical cancers (Cizkova et al, 2010; Karlsson et al, 2018; Zhang et al, 2019; Bersini et al, 2020; Cao et al, 2021; Halle et al, 2021). Here, LIMCH1 is linked to cervical carcinoma.